A genetic shield against a common chemotherapy side effect
A study in *Science Translational Medicine* reveals that a specific genetic variant, BDNF Val66Met, appears to protect colorectal cancer patients from developing peripheral neuropathy as a side effect of oxaliplatin chemotherapy. This research, published in February 2026, identifies a potential biomarker that could predict which patients are at lower risk for this debilitating nerve damage, a frequent complication that can limit treatment efficacy and impair quality of life. The findings offer a new avenue for personalizing cancer therapy and managing perioperative and post-treatment complications in surgical oncology.
Why it might matter to you: For surgeons managing colorectal cancer patients, this genetic insight could directly influence multidisciplinary treatment planning and preoperative discussions about adjuvant therapy risks. Identifying patients with this protective variant may allow for more aggressive or sustained chemotherapy regimens without the dose-limiting fear of severe neuropathy, potentially improving surgical outcomes and long-term survival. It underscores the growing role of pharmacogenomics in tailoring perioperative care and optimizing enhanced recovery protocols for oncology patients.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
